Drug Profile
Nangibotide - Inotrem
Alternative Names: CardioTREM; LR-12; Motrem; TREM-like-transcript-1-derived-peptideLatest Information Update: 10 Jan 2024
Price :
$50
*
At a glance
- Originator Inotrem
- Class Anti-infectives; Anti-inflammatories; Anti-ischaemics; Antivirals; Peptides
- Mechanism of Action TREML1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III COVID 2019 infections
- Phase II Septic shock
- Phase I Myocardial infarction
Most Recent Events
- 08 Jan 2024 Inotrem attends End of phase II meeting with the US FDA to finalize the design of a single phase III ACCURATE trial for Nangibotide in Septic shock
- 08 Jan 2024 Inotrem reaches agreement with the US FDA for single phase III registration (ACCURATE) trial for Nangibotide in Septic shock
- 08 Jan 2024 Inotrem plans a phase III ACCURATE trial for Septic shock in USA, Europe and Japan